The Nikkei Average extended its gains at the 7th midday close, rising more than ¥1,439 from the previous day. Namura Shipbuilding rose for the 3rd consecutive day after MLIT granted first approval for a supply assurance plan, with subsidies of up to approximately ¥49.9 billion expected. Oncolys surged to a new high, as expectations continued for the sales impact of Telomelysin and its inclusion in TOPIX.
The Nikkei Stock Average extended its gains at the 7th midday close, ending the morning session at ¥66,460.11. It was up ¥1,439.17 from the previous day, with the TSE Prime Market seeing a broad-based rise in share prices.
Namura Shipbuilding shares rose sharply for the 3rd consecutive day. The market appeared to continue buying the stock on expectations for the company's earnings and sector trends.
Oncolys surged to a new high. Expectations for the sales impact of Telomelysin and its inclusion in TOPIX were seen as driving the share price higher. MLIT's first approval of a supply assurance plan, along with associated subsidies of up to approximately ¥49.9 billion, also drew market attention.